U.S. markets closed
  • S&P 500

    4,471.37
    +33.11 (+0.75%)
     
  • Dow 30

    35,294.76
    +382.20 (+1.09%)
     
  • Nasdaq

    14,897.34
    +73.91 (+0.50%)
     
  • Russell 2000

    2,265.65
    -8.52 (-0.37%)
     
  • Crude Oil

    82.66
    +1.35 (+1.66%)
     
  • Gold

    1,768.10
    -29.80 (-1.66%)
     
  • Silver

    23.35
    -0.13 (-0.54%)
     
  • EUR/USD

    1.1606
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    1.5760
    +0.0570 (+3.75%)
     
  • GBP/USD

    1.3751
    +0.0074 (+0.54%)
     
  • USD/JPY

    114.2000
    +0.5230 (+0.46%)
     
  • BTC-USD

    60,356.58
    -1,009.51 (-1.65%)
     
  • CMC Crypto 200

    1,464.06
    +57.32 (+4.07%)
     
  • FTSE 100

    7,234.03
    +26.32 (+0.37%)
     
  • Nikkei 225

    29,068.63
    +517.70 (+1.81%)
     

Mirum (MIRM)-Takeda Collaborate for Liver Disease Drug in Japan

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Mirum Pharmaceuticals, Inc. MIRM announced that it has entered into an exclusive licensing agreement with Takeda Pharmaceutical TAK for the development and commercialization of its lead product candidate, maralixibat, for treating Alagille syndrome (“ALGS”), progressive familial intrahepatic cholestasis (“PFIC”) and biliary atresia, in Japan.

Per the latest deal, Takeda will lead the regulatory approval and commercialization of maralixibat in Japan, and will also be responsible for conducting studies in cholestatic indications.

The above partnership will leverage Takeda’s expertise and leadership in rare disease, gastroenterology and hepatology to advance maralixibat for rare pediatric liver diseases in Japan.

If successfully developed and upon potential approval, maralixibat can serve an area of significant unmet medical need for patients with cholestatic diseases such as ALGS and PFIC, in Japan.

Shares of Mirum have rallied 9.4% so far this year against the industry’s decrease of 1.4%.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

In March 2021, the FDA accepted the new drug application (“NDA”) for maralixibat to treat cholestatic pruritus in patients with ALGS aged one year and above. With the FDA granting a priority review to the NDA, a decision from the regulatory body is expected on Sep 29, 2021.

Currently there is no approved therapy for ALGS, a rare liver disease.

Earlier this month, Mirum submitted the marketing authorization application for maralixibat to the European Medicines Agency for the treatment of cholestatic liver disease in patients with ALGS.

Zacks Rank & Stocks to Consider

Mirum currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Spero Therapeutics, Inc. SPRO and Corvus Pharmaceuticals, Inc. CRVS, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Spero Therapeutics’ loss per share estimates have narrowed 8.2% for 2021 and 10.6% for 2022 over the past 60 days.

Corvus Pharmaceuticals’ loss per share estimates have narrowed 13.9% for 2021 and 7.2% for 2022, over the past 60 days. The stock has skyrocketed 139.6% year to date.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Corvus Pharmaceuticals, Inc. (CRVS) : Free Stock Analysis Report

Spero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report

Takeda Pharmaceutical Co. (TAK) : Free Stock Analysis Report

Mirum Pharmaceuticals, Inc. (MIRM) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research